Authors’ Disclosures
tumor
DIAZ, TUMOR
C.J. Paller reports grants from Believe Big and NCI, grants and other from Helixor during the conduct of the study. C.F. Meyer reports personal fees from Deciphera, AAdi, BioAlta, and Adaptimmune outside the submitted work. S. Gaillard reports personal fees from Arcus, Elevar Therapeutics, Immunogen, Lumanity, Novartis, Sermonix, Verastem; grants and personal fees from AstraZeneca, GSK; grants from Rigel, Iovance, PharmaMar, Tempest, and Genentech outside the submitted work; in addition, S. Gaillard has a patent to United States Patent Nos 10,258,604 and 10,905,659 issued and licensed. J.R. Brahmer reports personal fees and non-financial support from Merck; grants, personal fees, and non-financial support from Bristol Myers Squibb; grants and personal fees from AstraZeneca; personal fees from Regeneron, Sanofi, Johnson and Johnson, Amgen, Janssen, Genentech/Roche, and Eli Lilly outside the submitted work. Mrs. Page reports other from Helixor during the conduct of the study. L.A. Diaz reports personal fees from See below during the conduct of the study; personal fees from See Below outside the submitted work; in addition, L.A. Diaz has a patent to See below pending, issued, and licensed; and L.A. Diaz is a member of the board of directors of Jounce Therapeutics and Epitope. L.A. Diaz is a compensated consultant to PetDx, Innovatus CP, Se'er, Delfi, Blackstone, Kinnate, and Neophore. L.A. Diaz is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy. Some of these licenses and relationships are associated with equity or royalty payments to the inventors. L.A. Diaz holds equity in Epitope, Jounce Therapeutics, PetDx, Se'er, Delfi, Kinnate and Neophore. L.A. Diaz divested his equity in Personal Genome Diagnostics to LabCorp in February 2022 and divested his equity in Thrive Earlier Detection to Exact Biosciences in January 2021. L.A. Diaz's spouse holds equity in Amgen. The terms of all these arrangements are being managed by Memorial Sloan Kettering in accordance with their conflict-of-interest policy. No disclosures were reported by the other authors.